Compare Globus Medical Inc. Class A Common Stock (GMED) vs Welltower Inc. Common Stock (WELL) Price & Performance

Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.

GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.

WELL trades at $230.14, down 0.07% on the day, with a bullish technical signal supported by moving averages and a strong ADX trend indicator. The stock shows mixed earnings performance, missing Q4 2025 and Q2 2026 EPS estimates but beating in Q1 2026. Revenue grew to $10.67B in 2025, with net income of $936.85M, and is projected to rise to $12.6B in 2026. Analyst sentiment is strongly positive, with 71.43% buy ratings and a consensus price target of $257.08, indicating potential upside. Recent news highlights strategic acquisitions and positive coverage on senior housing demand trends.

Outlook: WELL benefits from strong demographic tailwinds in senior housing and robust analyst support, but high valuation multiples and earnings volatility pose risks. The stock's current price near support at $226 suggests a cautious entry point, with upside driven by execution on growth projections and sector tailwinds.